Your session is about to expire
← Back to Search
Triple Drug Therapy for Multiple Myeloma
Study Summary
This trial will assess the safety and efficacy of combining the drugs ruxolitinib, carfilzomib, and dexamethasone to treat multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Phase I
- Group 2: Phase II
Frequently Asked Questions
Are there still opportunities for enrolment in this clinical experiment?
"According to clinicaltrials.gov, this medical research endeavor is actively seeking participants. Initially posted on March 1st 2019, the most recent modification was made in September 10th 2022."
What is the ultimate aim of this trial?
"The primary outcome, Dose Limiting Toxicity (DLT), will be monitored for a time period of 4 months. Amgen has also reported that secondary objectives including Objective Response Rate (ORR), Duration of Response and Overall Survival are to be assessed as part of this trial. Specifically, ORR is defined as the best overall response achieved in accordance with International Myeloma Working Group criteria while Duration of Reponse refers to the amount of time between first objective status assessment and documented disease progression or death. Lastly, Overall Survival denotes duration from treatment initiation until patient's mortality due to any cause."
How many test subjects are currently taking part in this experiment?
"Affirmative. Per the information supplied on clinicaltrials.gov, this medical trial is actively recruiting participants. It was first released to the public on March 1st 2019 and has since been updated as recently as September 10th 2022. As of now, 48 individuals are needed across 2 distinct sites."
Is enrollment for this research open to individuals of all ages, even those under 30?
"According to the conditions of enrollment, any prospective participant must be at least 18 years old and not exceed 75."
Has Carfilzomib been researched in any other investigations?
"Currently, 653 clinical trials are actively studying the effects of Carfilzomib with 157 in their third phase. While Joliet, Illinois is home to most of these studies, other cities across 21841 locations are also taking part."
What maladies is Carfilzomib typically deployed to address?
"Carfilzomib is an efficacious option to combat ophthalmia, sympathetic and other communicable diseases. Additionally, it has been known to help those with branch retinal vein occlusion or macular edema manage their conditions."
Who is eligible to join this clinical research project?
"This clinical trial is searching for 48 viable candidates aged 18 to 75 with a documented history of relapsed and/or refractory multiple myeloma, serum monoclonal protein level ≥0.5 g/dL, urinary M-protein excretion of ≥200 mg over a 24-hour period, involved free light chain level ≥10 mg/dL plus an abnormal free light chain ratio, ANC ≥1000 cells/mm3 within 1 week prior to the start of treatment, platelet count depending on bone marrow plasmacytosis levels (≥75 ,000 or 50 ,000), total bilirubin ≤"
Share this study with friends
Copy Link
Messenger